231 related articles for article (PubMed ID: 27426862)
1. Fiix-prothrombin time monitoring improves warfarin anticoagulation outcome in atrial fibrillation: a systematic review of randomized trials comparing Fiix-warfarin or direct oral anticoagulants to standard PT-warfarin.
Onundarson PT; Arnar DO; Lund SH; Gudmundsdottir BR; Francis CW; Indridason OS
Int J Lab Hematol; 2016 May; 38 Suppl 1():78-90. PubMed ID: 27426862
[TBL] [Abstract][Full Text] [Related]
2. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
[TBL] [Abstract][Full Text] [Related]
3. Fiix-prothrombin time versus standard prothrombin time for monitoring of warfarin anticoagulation: a single centre, double-blind, randomised, non-inferiority trial.
Onundarson PT; Francis CW; Indridason OS; Arnar DO; Bjornsson ES; Magnusson MK; Juliusson SJ; Jensdottir HM; Vidarsson B; Gunnarsson PS; Lund SH; Gudmundsdottir BR
Lancet Haematol; 2015 Jun; 2(6):e231-40. PubMed ID: 26688233
[TBL] [Abstract][Full Text] [Related]
4. Reduced anticoagulation variability in patients on warfarin monitored with Fiix-prothrombin time associates with reduced thromboembolism: The Fiix-trial.
Oskarsdóttir AR; Gudmundsdottir BR; Indridason OS; Lund SH; Arnar DO; Bjornsson ES; Magnusson MK; Jensdottir HM; Vidarsson B; Francis CW; Onundarson PT
J Thromb Thrombolysis; 2017 May; 43(4):550-561. PubMed ID: 28214948
[TBL] [Abstract][Full Text] [Related]
5. Ignoring instead of chasing after coagulation factor VII during warfarin management: an interrupted time series study.
Oskarsdottir AR; Gudmundsdottir BR; Jensdottir HM; Flygenring B; Palsson R; Onundarson PT
Blood; 2021 May; 137(20):2745-2755. PubMed ID: 33512454
[TBL] [Abstract][Full Text] [Related]
6. During warfarin induction, the Fiix-prothrombin time reflects the anticoagulation level better than the standard prothrombin time.
Jonsson PI; Letertre L; Juliusson SJ; Gudmundsdottir BR; Francis CW; Onundarson PT
J Thromb Haemost; 2017 Jan; 15(1):131-139. PubMed ID: 27774726
[TBL] [Abstract][Full Text] [Related]
7. Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention.
Hirano T; Kaneko H; Mishina S; Wang F; Morita S
J Stroke Cerebrovasc Dis; 2017 Oct; 26(10):2102-2110. PubMed ID: 28532651
[TBL] [Abstract][Full Text] [Related]
8. Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-analysis.
Mhanna M; Beran A; Al-Abdouh A; Sajdeya O; Abdulsattar W; Srour O; Ayesh H; Alom M; Khuder SA; Hamouda D; Assaly R
Am J Ther; 2021 Jun; 28(5):e531-e539. PubMed ID: 34491953
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Direct Oral Anticoagulants Compared to Warfarin in Prevention of Thromboembolic Events Among Elderly Patients with Atrial Fibrillation.
Kailas SD; Thambuluru SR
Cureus; 2016 Oct; 8(10):e836. PubMed ID: 27900231
[TBL] [Abstract][Full Text] [Related]
10. The need for an adapted initiation nomogram during Fiix prothrombin time monitoring of warfarin.
Onundarson PT; Gudmundsdottir BR
J Thromb Thrombolysis; 2019 Nov; 48(4):685-689. PubMed ID: 31401717
[TBL] [Abstract][Full Text] [Related]
11. Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: An updated systematic review and meta-analysis of randomized controlled trials.
Ntaios G; Papavasileiou V; Diener HC; Makaritsis K; Michel P
Int J Stroke; 2017 Aug; 12(6):589-596. PubMed ID: 28730948
[TBL] [Abstract][Full Text] [Related]
12. Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies.
Deitelzweig S; Farmer C; Luo X; Vo L; Li X; Hamilton M; Horblyuk R; Ashaye A
Curr Med Res Opin; 2017 Sep; 33(9):1583-1594. PubMed ID: 28644048
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis.
Savarese G; Giugliano RP; Rosano GM; McMurray J; Magnani G; Filippatos G; Dellegrottaglie S; Lund LH; Trimarco B; Perrone-Filardi P
JACC Heart Fail; 2016 Nov; 4(11):870-880. PubMed ID: 27614940
[TBL] [Abstract][Full Text] [Related]
14. A single test to assay warfarin, dabigatran, rivaroxaban, apixaban, unfractionated heparin, and enoxaparin in plasma.
Letertre LR; Gudmundsdottir BR; Francis CW; Gosselin RC; Skeppholm M; Malmstrom RE; Moll S; Hawes E; Francart S; Onundarson PT
J Thromb Haemost; 2016 May; 14(5):1043-53. PubMed ID: 26924677
[TBL] [Abstract][Full Text] [Related]
15. Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation.
Oertel LB; Fogerty AE
J Am Assoc Nurse Pract; 2017 Sep; 29(9):551-561. PubMed ID: 28805310
[TBL] [Abstract][Full Text] [Related]
16. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Vo L
Curr Med Res Opin; 2017 Sep; 33(9):1595-1604. PubMed ID: 28635338
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
18. Direct Oral Anticoagulants vs. Vitamin K Antagonists in Atrial Fibrillation Patients at Risk of Falling: A Meta-Analysis.
Gao X; Huang D; Hu Y; Chen Y; Zhang H; Liu F; Luo J
Front Cardiovasc Med; 2022; 9():833329. PubMed ID: 35615562
[TBL] [Abstract][Full Text] [Related]
19. Impact of Polypharmacy and P-Glycoprotein- and CYP3A4-Modulating Drugs on Safety and Efficacy of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation.
Harskamp RE; Teichert M; Lucassen WAM; van Weert HCPM; Lopes RD
Cardiovasc Drugs Ther; 2019 Oct; 33(5):615-623. PubMed ID: 31520256
[TBL] [Abstract][Full Text] [Related]
20. Circadian variations in laboratory measurements of coagulation assays after administration of rivaroxaban or warfarin in patients with nonvalvular atrial fibrillation.
Hitaka Y; Ogawa M; Zhang B; Goto S; Nagata Y; Morii J; Imaizumi S; Yasuda T; Matsumoto N; Matsunaga A; Saku K
J Cardiol; 2016 Dec; 68(6):529-535. PubMed ID: 26987789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
